Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome

Rigosertib has demonstrated therapeutic activity for patients with high-risk myelodysplastic syndrome (MDS) in clinical trials. However, the role of rigosertib in MDS has not been thoroughly characterized. In this study, we found out that rigosertib induced apoptosis, blocked the cell cycle at the G...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Rep
Main Authors: Xu, Feng, He, Qi, Li, Xiao, Chang, Chun-Kang, Wu, Ling-Yun, Zhang, Zheng, Liu, Li, Shi, Wen-Hui, Zhu, Yang, Zhao, You-Shan, Gu, Shu-Cheng, Fei, Cheng-Ming, Guo, Juan, Wu, Dong, Zhou, Liyu
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4255183/
https://ncbi.nlm.nih.gov/pubmed/25472472
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep07310
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados